Long Non-coding RNAs, Novel Culprits, or Bodyguards in Neurodegenerative Diseases

Ding-Qi Wang,1,7 Peng Fu,2,7 Chengye Yao,3,7 Ling-Shuang Zhu,1 Tong-Yao Hou,1 Jian-Guo Chen,4 Youming Lu,5 Dan Liu,5,6 and Ling-Qiang Zhu1,5

1Department of Pathophysiology, Key Lab of Neurological Disorder of Education Ministry, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, PRC; 2Department of Neurosurgery, Union Hospital, Huazhong University of Science and Technology, Jiefang Avenue No. 1277, 430022 Wuhan, PRC; 3Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, PRC; 4Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, PRC; 5The Institute for Brain Research, Collaborative Innovation Center for Brain Science, Huazhong University of Science and Technology, Wuhan 430030, PRC; 6Department of Medical Genetics, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, PRC

Long non-coding RNA (IncRNA) is a kind of non-coding RNA (ncRNA), with a length of 200 nt to 100 kb, that lacks a significant open reading frame (ORF) encoding a protein. IncRNAs are widely implicated in various physiological and pathological processes, such as epigenetic regulation, cell cycle regulation, cell differentiation regulation, cancer, and neurodegenerative diseases, through their interactions with chromatin, protein, and other RNAs. Numerous studies have suggested that IncRNAs are closely linked with the occurrence and development of a variety of diseases, especially neurodegenerative diseases, of which the etiologies are complicated and the underlying mechanisms remain elusive. Determining the roles of IncRNA in the pathogenesis of neurodegenerative diseases will not only deepen understanding of the physiological and pathological processes that occur in those diseases but also provide new ideas and solutions for their diagnosis and prevention. This review aims to highlight the progress of IncRNA research in the pathological and behavioral changes of neurodegenerative diseases. Specifically, we focus on how IncRNA dysfunctions are involved in the pathogenesis of Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis.

In the human genome, less than 2% of the transcripts encode proteins, and the remaining 98%–99% are non-coding RNAs (ncRNAs).1 ncRNAs can be divided into two categories: short non-coding RNA (short/small ncRNA) and long non-coding RNA (long ncRNA). No particularly stringent boundary exists between these categories, except for the length of the ncRNA nucleotide sequence. An ncRNA of greater than 200 nt is defined as an IncRNA. In recent years, with the rapid development of RNA sequencing technology and computational methods, IncRNA has been gradually recognized by researchers. IncRNA is widely distributed among animals, plants, yeasts, and even viruses, and we now know that IncRNA can be involved in X chromosome silencing, genomic imprinting, chromatin modification, transcriptional activation, transcriptional interference, epigenetic regulation, and other important regulatory processes.2

These molecules are related to cell proliferation and differentiation, metabolism, and other physiological processes, as well as various pathological processes. The mutation and abnormal regulation of IncRNAs plays an important role in many human diseases, such as the occurrence and development of cancer and neurodegenerative diseases.3,5

Neurodegenerative disease is characterized by the loss of neurons or myelin in the brain and spinal cord, deteriorating over time and leading to dysfunction.5,7 The brain and spinal cord comprise neurons that have different functions, such as controlling motion, processing sensory information, and making decisions. The cells of the brain and spinal cord are generally not regenerated; thus, excessive damage can be devastating and irreversible. Neurodegenerative diseases are widespread worldwide. The long course and lack of effective treatment of these diseases impose a heavy burden on individuals, families, and society. In recent years, many studies have shown that IncRNA can participate in the regulation of neurodegenerative disease occurrence and development. Based on existing research results, this paper focuses on IncRNA in several common neurodegenerative diseases. We made a summary of IncRNAs involved in this review (Table 1).

Classification, Origin, and Function of IncRNA

IncRNAs were first found in rat full-length cDNA sequence libraries, usually overlapping or dispersed between transcripts. According to location and context, IncRNA can be divided into five categories, including inter-gene long-chain non-coding RNA (intergenic...
**Table 1. Dysregulated lncRNAs in Neurodegenerative Diseases**

| lncRNAs                  | Description                                                                 | Associated Disease | Culprit or Bodyguard | Biological Function                                                                                                                                 |
|--------------------------|-----------------------------------------------------------------------------|--------------------|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| BACE1-AS                 | transcribe from the antisense protein-coding BACE 1 gene                    | AD                 | culprit              | bind to BACE1 and increase the stability of its mRNA, thereby promoting the synthesis of BACE1 protein, and further increase the production of Aβ of cells |
| BC200                    | homologous with rodent Bc1 lncRNA; the earliest specific example showed lncRNAs conservation | AD                 | culprit              | induce APP mRNA translation via association with FMRP and then aggregate the accumulation of Aβ in the brain                                         |
| 17A                      | embedded in the human G-protein-coupled receptor 51 gene                   | AD                 | culprit              | impair GABAB signaling pathway by decreasing GABAB R2 transcription                                                                                  |
| NAT-Rad18                | transcribed from the antisense of protein coding gene Rad18                | AD                 | culprit              | down the expression of DNA repair protein Rad18 and enhance susceptibility to neuronal apoptosis                                                   |
| 51A                      | an antisense transcript of intron 1 of the SORL1 gene                      | AD                 | culprit              | altering the spliced form of SORL1 mRNA and resulting in Aβ42 accumulation                                                                         |
| GDNFOS                   | transcribed from the opposite strand of GDNF gene                          | AD                 | culprit              | negatively regulate the expression of GDNF                                                                                                           |
| HttAS_v1                 | antisense transcript of the Htt gene                                        | HD                 | bodyguard            | reduce endogenous HTT transcript levels                                                                                                               |
| BDNFOS                   | antisense transcription product of BDNF                                      | HD                 | bodyguard            | upregulates the transcription of BDNF and have a protective effect on neurons                                                                        |
| NEAT1                    | a nuclear-enriched ncRNA essential for the formation and maintenance of paraspeckles | HD                 | bodyguard            | essential for the integrity of the nuclear paraspeckle substructure; increase viability under oxidative stress                                      |
| HAR1F and HAR1R          | antisense transcripts of the first HAR1 gene                                | HD                 | bodyguard            | involved in neurotransmission, memory structure, and synaptic plasticity in the mature brain                                                          |
| DGCR5                    | a transcript of DiGeorge critical region 5                                  | HD                 | bodyguard            | include a genome binding site for REST and play an important transcriptional regulatory role in HD                                                    |
| MEG3                     | the human homolog of the mouse maternally expressed gene Gt02, the first implanted gene identified on the mouse distal chromosome 12 | HD                 | culprit              | alter gene expression in response to neuronal activity                                                                                              |
| ABHD11-AS1               | homologous with rodent Abhd11os lncRNA                                     | HD                 | bodyguard            | attenuate the toxicity of Htt mRNA                                                                                                                   |
| NaPINK1                  | transcribed from the antisense of PINK1 locus                              | PD                 | bodyguard            | stabilize PINK1 expression                                                                                                                         |
| AS Uchl1                 | antisense transcript of Uchl1                                             | PD                 | bodyguard            | regulate the expression of UCHL1 at the post-transcriptional level, thus promoting the translation process and increasing protein synthesis            |
| HOTAIR                   | antisense intergenic RNA transcribed from the HOXC locus                   | PD                 | culprit              | increase the stability of LRRK2 mRNA and upregulated its expression, thus inducing DA neuronal apoptosis                                             |
| MALAT1                   | also known as NEAT2 and is a highly conserved ncRNA highly expressed in neurons | PD                 | culprit              | upregulate a-synuclein expression, thus driving the pathogenesis of PD                                                                            |

LncRNA, also known as long intergenic ncRNA or lincRNA, which is produced by the transcription of spacer sequences between genes encoded in the genome, intron long-chain non-coding RNA (intronic lncRNA, which is completely transcribed from introns within a protein-coding gene), sense long-chain non-coding RNA (sense lncRNA, transcribed from the coding strand of a protein-coding gene and partly or completely overlapping the gene exons), antisense long-chain non-coding RNA (antisense lncRNA, transcribed from the non-coding strand of a gene), and bidirectional long-chain non-coding RNA (bidirectional lncRNA, transcribed from the promoter region in two opposite directions) (Table 2).\(^9\) At present, the source of lncRNA is not very clear. Ponting et al.\(^10\) thought that lncRNA may have arisen in the following ways: mutations in the open reading frames (ORFs) of protein-coding genes during early evolution, leading to structural disruption and then to lncRNA; chromatin recombination resulting in two originally distant non-transcript fragments coming together to produce lncRNA; duplication of non-coding genes formed by reverse transcription transposition; repetition of a certain sequence, resulting in lncRNA with adjacent repeat sequences; and DNA sequence insertion by a transposable element to produce functional lncRNA. Although many lncRNAs have no common origin, they play similar roles in
the regulation of gene expression, and their most important function may be epigenetic regulation of the genome.10

lncRNA is located in the nucleus or cytoplasm and lacks the ability to encode proteins. Initially, biologists thought that lncRNA had no biological function and was only the “noise” of genomic transcription, a byproduct of the activity of RNA polymerase II (RNA PII).11 However, with further research, people have gradually gained a deeper understanding of lncRNA, its presence in the subcellular structure, and its ability to regulate protein localization and activity. LncRNA can regulate gene expression by recruiting RNA PII or inducing chromatin recombination.12 Compared with small ncRNA, lncRNA has a relatively long chain of nucleotides, meaning that the internal folding of lncRNA molecules can form many specific and complex secondary spatial structures; these structures provide multiple sites, allowing interaction with a number of other molecules to perform biological functions involved in regulating growth and development,13 cell proliferation and differentiation,14 apoptosis,15 and other processes. Meanwhile, a variety of clinical diseases are closely related to lncRNA.16 Although the mechanisms of lncRNA involvement in various diseases are not fully understood, this study shows that lncRNA is widely involved in various regulatory mechanisms. LncRNA can be released after being activated by cellular stress and then form complexes with the ribosome to regulate gene expression. Molecular studies have suggested that lncRNA may work in the following modes. (1) Interacting with chromatin: LncRNA regulates the upstream promoter regions of coding genes by mediating chromatin remodeling and histone modification and then affects the expression of related genes. (2) Interacting with proteins: LncRNA can be used as a guiding molecule for a single protein or it can act as a scaffold molecule for two or more proteins to synthesize a protein complex and then recruit the complex to corresponding locations in coding genes to regulate the expression of downstream genes. In addition, LncRNA can also be used as a bait molecule for proteins. It can transfer proteins that are bound to the genome and change their intracellular localization, thereby inhibiting gene transcription and expression. (3) Interaction with other RNAs: many specific microRNA (miRNA) recognition sites are present in LncRNA. On the one hand, miRNAs can affect the stability of lncRNA in vivo, mediating the degradation of lncRNA and thus regulating its cell biological functions. On the other hand, lncRNA can act as a bait molecule for miRNA, targeting miRNA by target mimicry and inhibiting its further action, thus indirectly regulating the expression of miRNA target genes. In addition, lncRNA can act as an endogenous competitor of miRNA by binding miRNA-binding sites on mRNA.17,18 Moreover, lncRNA can regulate mRNA at the post-transcriptional level by mRNA transcription inhibition, splicing, and degradation.19

**Table 2. Classification of IncRNAs**

| Classification | Description | Example |
|---------------|------------|---------|
| Intergenic    | produced by the transcription of spacer sequences between genes encoded in the genome | XIST, TMEM161B-AS, HARI, NEAT1, TUG1 |
| Intergenic    | transcribed from introns within a protein-coding gene | Lnc-OR51B4-3, KCNIP4-IT1 |
| Sense         | transcribed from the coding strand of a protein-coding gene and partly or completely overlapping the gene exons | SNHG4 |
| Antisense     | transcribed from the non-coding strand of a gene | BACE1-AS, MALAT1, Lnc-LRR1, TUSC7 |
| Bidirectional | transcribed from the promoter region in two opposite directions | Hoxa11as, IGF2AS, HOTAIR RM1 |

Brain cytoplasmic (BC) RNA is another lncRNA that causes AD and brain aging. Mouse BC1 RNA and human BC200 RNA are lncRNA transcripts that are transported as ribonucleoprotein particles to the dendritic processes and bind to poly(A)-binding protein (PABP1), a regulator of translation initiation, thus regulating gene expression at the translational level.24 BC200 can interact with some RNA-binding proteins involved in aberrant transport of mRNA, leading to abnormal protein localization. Overexpression of BC200 in AD and the aging brain may cause synaptic/dendritic degeneration. Mus et al.25 found that the level of BC200 in the AD-affected brain region Brodmann area 9 was higher than that in the normal brain, and the relative level of BC200 RNA in the affected region increased in parallel with AD severity. Simultaneously, they found that in the advanced stage of AD, BC200 RNA often assumed a clustered perikaryal localization, indicating that dendritic loss is accompanied by somatic overexpression. Mus et al. concluded that this was a stress compensation mechanism initiated by dendritic sprouting and remodeling in AD degenerative lesions; they also thought that the abnormal localization and distribution of BC200 might be responsible for the cause and course of the disease. Whether BC200 overexpression in brain tissue is the cause of AD or an accompanying compensatory response will require further testing and confirmation.26 Recently, Zhang et al.27 showed that BC1 induces APP mRNA translation via association with a fragile X syndrome protein (FMRP). Inhibition of BC1 or
and plays an important role in DNA repair following nerve injury. After involved in proliferating cell nuclear antigen (PCNA) ubiquitination to neuronal apoptosis; excess cell loss may contribute to AD. lncRNA lncRNA NAT-Rad18, which exerts post-transcriptional control over reduction of A\(\beta\)-induced apoptosis, the Rad18 gene antisense transcription product can bind to BACE1 mRNA, increase the stability of the latter, and promote the synthesis of BACE1 protein, further increasing the production of cell Aβ. miRNA miR-485-5p has an inhibitory effect on BACE1 expression, whereas mRNA mir-485-5p and BACE1 AS have the same binding sites on BACE1 mRNA, so their regulation of BACE1 mRNA expression is antagonistic. BC1 induces APP mRNA translation via association with FMRP. Under inflammatory stimulation, IncRNA-17A can direct GPR51 splicing to produce GABAB receptor isoform variant B, thus causing the synthesis of a non-functional GABAB receptor. In addition, overexpression of 17A causes overproduction of Aβ.

Under inflammatory stimulation, IncRNA-17A can direct G-protein-coupled receptor 51 (GPR51) splicing to produce isoform variant B of the B-type receptor for the neurotransmitter g-aminobutyric acid (GABA; GABAB receptor). Because only the canonical variant, isoform A, contains the complete C-terminal portion needed to interact with GABAB R1 to generate a functional heterodimeric receptor, this alternative splicing causes the synthesis of a non-functional GABAB receptor. In addition, the overexpression of 17A causes overproduction of Aβ.

Some lncRNA polymorphisms are associated with AD pathogenesis. For example, rs7990916 (T > C) located in the lincRNA TCONS_00021856/fi-51A is an antisense transcript of intron 1 of the sorting protein-related receptor 1 (SORL1) gene, resulting in Aβ42 accumulation by altering the splice form of SORL1 mRNA. Zhou et al. have found 24 upregulated and 84 downregulated lncRNAs in AD patients compared with controls, most being intergenic. Gene set enrichment analysis identified a downregulated lncRNA, n341006, in association with the protein ubiquitination pathway, and a significantly upregulated lncRNA, n336934, linked to cholesterol homeostasis. The lncRNA GDNFOS is a transcriptional product transcribed from the opposite strand of glial-cell-line-derived neurotrophic factor (GDNF) that may negatively regulate the expression of GDNF to promote the course of AD. Neurroblastoma differentiation marker 29 (NDM29), which is an RNA polymerase (pol) III-transcribed ncRNA, can be promoted by inflammatory stimuli and induces APP synthesis, leading to the increase of Aβ secretion and the process may occur in AD (Figure 1). Given that aging is also one of the major risks of neurodegenerative diseases, the role of lncRNA in aging cannot be overlooked. Zhang et al. have identified 97 significantly upregulated and 114 significantly downregulated lncRNA transcripts from the senescence-accelerated mouse prone 8 (SAMP8) and senescence-accelerated mouse resistant 1 (SAMR1) models. These significantly dysregulated lncRNAs were involved in nerve growth factor term, the mitogen-activated protein kinase signaling pathway, and the AD pathway, thus regulating the development of AD.

IncRNA and Huntington’s Disease
Huntington’s disease (HD), also known as chorea or Huntington’s chorea, is an autosomal dominant neurodegenerative disease characterized by progressive dyskinesias and mental decline.

In HD, the Huntingtin (Htt) protein accumulates gradually in cells, forming large molecules that accumulate in the brain, affecting the function of nerve cells, and resulting in the progressive death of the striatum and cortical nerve cells. IncRNA HtasAS_v1 is an antisense transcript of the Htt gene and is expressed at a low level in the frontal cortex of HD patients, leading to high expression of Htt mRNA, which in turn promotes HD pathogenesis. Htt modulates the nuclear translocation of the transcriptional repressor RE1 silencing transcription factor/neuron-restrictive silencer factor (REST/NRFSF). Mutant Htt promotes abnormal nuclear-cytoplasmic transport of REST/NRFSF and then leads to abnormal expression of REST target genes, including protein-coding and non-coding genes (Figure 2).

BDNFOS is an antisense transcription product of brain-derived neurotrophic factor (BDNF), which upregulates the transcription of BDNF and the translation of BDNF-mRNA in HD. Small interfering RNA (siRNA) treatment with BDNFOS can induce Htt expression. BDNFOS has a protective effect on neurons and improves the HD phenotype, which is of some positive significance in the prevention and treatment of HD.

NEAT1 (nuclear paraspeckle assembly transcript 1) is a nuclear-enriched ncRNA essential for the formation and maintenance of
The expression of HttAS-v1 is decreased in HD patients, resulting in high expression of Htt mRNA. Htt is involved in the translocation of REST/NRSF into the nucleus, retaining REST/NRSF in the cytosol and thereby preventing REST/NRSF target gene repression.

To detect ncRNAs involved in the pathogenesis of HD, one study examined the ncRNA expression profile of human HD brain tissue and found that the expression of the IncRNAs HAR1F and HAR1R, which are antisense transcripts of the first human accelerated region 1 (HAR1) gene, was significantly reduced in the striatum. These IncRNAs are involved in neurotransmission, memory structure, and synaptic plasticity in the mature brain, and their aberrant expression is also associated with HD. The same study also demonstrated that abnormal REST nuclear-cytoplasmic exchange in the striatum of HD led to effective transcriptional repression of HAR1. The IncRNA DGCR5 is a transcript of DiGeorge critical region 5 (DGCR5) and includes a genome-binding site for REST, which plays an important transcriptional regulatory role in HD. The expression of the IncRNA MEG3, encoded by maternally expressed gene 3 (MEG3), was downregulated in HD brain tissue, and its downregulation was also inhibited by REST. There is much disparate research showing that MEG3 may be an important epigenetic regulator in the developing and adult human brain, which may stably alter gene expression in response to neuronal activity. If so, the downregulation of MEG3 in HD could plausibly have serious consequences.

Overexpression of the IncRNA Abhd11os (ABHD11-AS1 in humans) attenuates the toxicity of Htt mRNA in murine models of HD. Studies have shown that knocking out the Abhd11os gene in the HD mouse model produces neurotoxicity, whereas overexpression of Abhd11os has a neuroprotective effect.

**IncRNA and Parkinson’s Disease**

Parkinson’s disease (PD) is a chronic progressive movement disorder caused by loss of brain dopaminergic neurons. PD is a common neurodegenerative disease in the elderly, with clinical symptoms such as resting tremor, muscle tension instability, and posture instability.

Loss or overexpression of PTEN-induced kinase 1 (PINK1) results in abnormal dopamine release and impaired motor function. NaPINK1 is a human-specific ncRNA transcribed from the antisense orientation of the PINK1 locus that can stabilize PINK1 expression. NaPINK1 silencing results in decreased PINK1 expression in neurons.

The ubiquitin carboxy-terminal hydrolase L1 gene (Uch1l) has been shown to be closely related to brain function and neurodegenerative diseases. An antisense transcript of Uch1l, AS Uch1l, can regulate the expression of UCHL1 at the post-transcriptional level and enhance contact between post-transcriptional mRNA and polysaccharides, thus promoting the translation process and increasing protein synthesis. This activity has been disrupted in patients with familial PD, and studies have reported losses of UCHL1 activity in many other neurodegenerative diseases. Regulation of Uch1l expression can provide new ideas for PD treatment.

Previous studies have shown that a-synuclein aggregation is the driving force in PD pathogenesis. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), also known as nuclear-enriched abundant transcript 2 (NEAT2), is a highly conserved ncRNA highly expressed in neurons. Recently, research has shown MALAT1 overexpression upregulated a-synuclein expression, whereas inhibition of MALAT1 downregulated its expression only in the protein level rather than the mRNA level. Giving β-asarone, the major ingredient of Acorus tatarinowii Schott, can decrease the expression levels of MALAT1 and a-synuclein in the midbrain tissue of PD mice, suggesting β-asarone as a potential therapeutic agent for PD.

Leucine-rich repeat kinase 2 (LRRK-2) is thought to be involved in the initiation/development of PD. Recently, research has shown that HOTAIR (Hox transcript antisense intergenic RNA), an approximately 2.2-kb-long noncoding RNA transcribed from the HOXC locus, is upregulated in a mouse model of PD that is developed by intraperitoneal injection of MPTP. The upregulated HOTAIR can specifically increase the stability of LRRK2 mRNA and upregulated its expression, thus inducing DA neuronal apoptosis.

**IncRNA and Amyotrophic Lateral Sclerosis**

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that has no effective therapeutic means at present. ALS is characterized by the progressive paralysis of the limbs and muscles involved in
speech, swallowing, and respiration due to the progressive degeneration of spontaneous motor neurons. In 2011, the repeated amplification of a six-nucleotide motif (GGGGCC) in the protein-coding gene C9ORF72 (chromosome 9 ORF 72) became the first identified causative mutation in ALS and front temporal dementia (FTD). Non-coding transcripts have now also been identified at the C9ORF72 locus. The transcription of the C9ORF72 repeats is bidirectional, producing both sense and antisense RNAs, both of which are elevated in the brains of ALS patients, and these transcripts are localized predominantly in the nucleus. C9ORF72 antisense lncRNA can inhibit C9ORF72 mRNA, thereby inhibiting gene expression. However, even if the expression of a disease-related gene is corrected in fibroblasts derived from a patient, the disease still cannot be treated.

TDP43 (TAR DNA-binding domain protein 43) and FUS/TLS (fused in sarcoma/translated in liposarcoma) are RNA-binding proteins that are predominantly located in the nucleus and play a role in regulating RNA metabolism. Studies have shown that abnormal accumulation of FUS/TLS and TDP43 in the cytosol directly leads to the misfolding of wtSOD1 (wild-type Cu/Zn superoxide dismutase) in non-SOD1 FALS (familial ALS) and SALS (sporadic ALS), which means that they constitute common molecular pathogenesis mechanisms of ALS.

A previous study found that lncRNA could recruit FUS/TLS to the genomic locus that encodes cyclin D1, where cyclin D1 transcription is repressed in response to DNA damage signals, resulting in increased tolerance to apoptosis signals.

**Conclusions**

With the rapid development of RNA sequencing technology and computational methods, lncRNA has gradually been recognized by researchers, and the current research regarding lncRNA in neurological diseases has made some progress. The expression patterns of most lncRNAs are more tissue specific than those of their respective mRNAs, suggesting that lncRNAs can be used as molecular markers for disease diagnosis and drug design. In view of the specificity effects of certain lncRNAs, targeted therapeutic drugs can be designed to minimize the impact of other unrelated genes to achieve the purpose of personalized treatment. However, the evidence for the association of lncRNAs with neurological disease is mainly due to differences in expression, and only a few functions of lncRNAs have been clearly demonstrated. Dynamic analysis of changes in the body is constrained by available analytical techniques. Along with the specificity of lncRNA itself, such as its numerous species, the small amount of information contained in the original sequences and the limitation of research methods have contributed to the superficiality of our knowledge of the mechanism of lncRNA action and of other regulatory mechanisms. It remains necessary to continue to pursue in-depth research into the effects of lncRNA and other regulatory mechanisms affected by the microenvironment of the body.

**CONFLICTS OF INTEREST**

The authors have declared that there are no conflicts of interest.

**ACKNOWLEDGMENTS**

This study is supported partially by the National Natural Science Foundation of China (91632114, 31571039, 81771150, 81761138043, 51627807, and 31721002), the National Program for Support of Top-Notch Young Professionals and Academic Frontier
REFERENCES

1. Birney, E., Stamatoyannopoulos, J.A., Dutta, A., Guigó, R., Gingeras, T.R., Margulies, E.H., Veng, Z., Snyder, M., Dermitzakis, E.T., Thurman, R.E., et al.; ENCODE Project Consortium; NISC Comparative Sequencing Program; Baylor College of Medicine Human Genome Sequencing Center; Washington University Genome Sequencing Center; Broad Institute; Children's Hospital Oakland Research Institute (2007). Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447, 799–816.

2. Quinn, J.J., and Chang, H.Y. (2016). Unique features of long non-coding RNA biogenesis and function. Nat. Rev. Genet. 17, 47–62.

3. Wang, W.T., Sun, Y.M., Huang, W., He, B., Zhao, Y.N., and Chen, Y.Q. (2016). Genome-wide long non-coding RNA analysis identified circulating lncRNAs as Novel non-invasive diagnostic biomarkers for gynaecological disease. Sci. Rep. 6, 23343.

4. Sunwoo, J.S., Lee, S.T., Im, W., Lee, M., Byun, J.I., Jung, K.H., Park, K.I., Jung, K.Y., Lee, S.K., Cth, K., et al. (2017). Altered expression of the long noncoding RNA NEAT1 in Huntington's disease. Mol. Neurobiol. 54, 1577–1586.

5. Yuan, J., Yue, H., Zhang, M., Luo, J., Liu, L., Wu, W., Xiao, T., Chen, X., Chen, X., Zhang, D., et al. (2016). Transcriptional profiling analysis and functional prediction of long noncoding RNAs in cancer. Oncotarget 7, 8131–8142.

6. Ng, S.Y., Lin, L., Soh, B.S., and Stanton, L.W. (2013). Long noncoding RNAs in development and disease of the central nervous system. Trends Genet. 29, 461–468.

7. Appel, S.H., Smith, R.G., and Le, W.D. (1996). Immune-mediated cell death in neurodegenerative disease. Adv. Neurol. 69, 153–159.

8. Mercer, T.R., Dinger, M.E., and Mattick, J.S. (2009). Long non-coding RNAs: insights into functions. Nat. Rev. Genet. 10, 155–165.

9. Ma, L., Bajic, V.B., and Zhang, Z. (2013). On the classification of long-non-coding RNAs. RNA Biol. 10, 925–933.

10. Ponting, C.P., Oliver, P.L., and Reik, W. (2008). Evolution and functions of long non-coding RNAs. Cell 136, 629–641.

11. Kung, J.T., Colognori, D., and Lee, J.T. (2013). Long noncoding RNAs: past, present, and future. Genetics 193, 651–669.

12. Fatemi, R.P., Velmeshev, D., and Faghihi, M.A. (2014). De-repressing lincRNA-targeted genes to upregulate gene expression: focus on small molecule therapeutics. Mol. Ther. Nucleic Acids 3, e196.

13. Matouk, I.I., DeGroot, N., Mezan, S., Ayesh, S., Abu-lal., R., Hochberg, A., and Galun, E. (2007). The H19 non-coding RNA is essential for human tumor growth. PLoS One 2, e485.

14. Prensner, J.R., Iyer, M.K., Balbin, O.A., Dhanasekaran, S.M., Cao, Q., Brenner, J.C., Laxman, B., Asangani, I.A., Grasso, C.S., Kominsky, H.D., et al. (2011). Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lncRNA implicated in disease progression. Nat. Biotechnol. 29, 742–749.

15. Huarte, M., Guttman, M., Feldser, D., Garber, M., Schones, D.E., and Natarajan, R. (2013). Novel long noncoding RNAs are regulated by angiotensin II in vascular smooth muscle cells. Circ. Res. 113, 266–278.

16. Johnsson, P., Lipovich, L., Grandér, D., and Morris, K.V. (2014). Evolutionary conservation of long non-coding RNAs: sequence, structure, function. Biochim. Biophys. Acta 1840, 1063–1071.

17. Wu, P., Zuo, X., Deng, H., Liu, X., Liu, L., and Ji, A. (2013). Roles of long noncoding RNAs in brain development, functional diversification and neurodegenerative diseases. Brain Res. Bull. 97, 69–80.

18. Hardy, J., and Selkoe, D.J. (2002). The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297, 353–356.
REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 35, 76–83.

39. Lipovich, L., Dachet, F., Cai, J., Bagla, S., Balan, K., Jia, H., and Loeb, J.A. (2012). Activity-dependent human brain coding/noncoding gene regulatory networks. Genetics 192, 1133–1148.

40. Clemson, C.M., Hutchinson, J.N., Sara, S.A., Ensminger, A.W., Fox, A.H., Chess, A., and Lawrence, J.B. (2009). An architectural role for a nucleic noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. Mol. Cell 33, 717–726.

41. Li, X., Wu, Z., Fu, X., and Han, W. (2014). IncRNAs: insights into their function and mechanics in underlying disorders. Mutat. Res. Rev. Mutat. Res. 762, 1–21.

42. Johnson, R., Richter, N., Jauch, R., Gaughwin, P.M., Zuccato, C., Cattaneo, E., and Stanton, L.W. (2010). Human accelerated region 1 noncoding RNA is repressed by REST in Huntington’s disease. Physiol. Genomics 41, 269–274.

43. Johnson, R., Teh, C.H., Jia, H., Vanisri, R.R., Pandey, T., Lu, Z.H., Buckley, N.J., Stanton, L.W., and Lipovich, L. (2009). Regulation of neural macroRNAs by the transcriptional repressor REST. RNA 15, 85–96.

44. Johnson, R. (2012). Long non-coding RNAs in Huntington’s disease neurodegeneration. Neurobiol. Dis. 46, 245–254.

45. Francelle, L., Galvan, L., Gaillard, M.C., Petit, F., Bernay, B., Guillermier, M., Bonvento, G., Dufour, N., Elalouf, J.M., Hantraye, P., et al. (2015). Striatal long non-coding RNA AbdIlos is neuroprotective against an N-terminal fragment of mutant huntingtin in vivo. Neurobiol. Aging 36, 1601.e7–1601.e16.

46. Chiba, M., Kiyosawa, H., Hiraïwa, N., Ohkohchi, N., and Yasue, H. (2009). Existence of Pink1 antisense RNAs in mouse and their localization. Cytogenet. Genome Res. 126, 259–276.

47. Scheele, C., Petrovic, N., Faghihi, M.A., Lassmann, T., Fredriksson, K., Rooyackers, O., Wahlestedt, C., Good, L., and Timmons, J.A. (2007). The human PINK1 locus is regulated in vivo by a non-coding natural antisense RNA during modulation of mitochondrial function. BMC Genomics 8, 74.

48. Carrieri, C., Cimatti, L., Biagioli, M., Beugnet, A., Zucchelli, S., Fedele, S., Pesce, E., Ferrer, J., Collavin, L., Santoro, C., et al. (2012). Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat. Nature 491, 454–457.

49. Carrieri, C., Forrest, A.R., Santoro, C., Persichetti, F., Carninci, P., Zucchelli, S., and Gustincich, S. (2015). Expression analysis of the long non-coding RNA antisense to Uchl1 (AS Uchl1) during dopaminergic cells’ differentiation in vitro and in neurochemical models of Parkinson’s disease. Front. Cell. Neurosci. 9, 114.

50. Stefanis, L. (2012). α-Synuclein in Parkinson’s disease. Cold Spring Harb. Perspect. Med. 2, a009399.

51. Bernard, D., Prasanth, K.V., Tripathi, V., Colasse, S., Nakamura, T., Xuan, Z., Zhang, M.Q., Sede, F., Jourend, L., Coulper, F., et al. (2010). A long nuclear-retained non-coding RNA regulates synaptogenesis by modulating gene expression. EMBO J. 29, 3082–3093.

52. Zhang, Q.S., Wang, Z.H., Zhang, J.L., Duan, Y.L., Li, G.F., and Zheng, D.L. (2016). Beta-asarone protects against MPTP-induced Parkinson’s disease via regulating long non-coding RNA MALAT1 and inhibiting α-synuclein protein expression. Biomed. Pharmacother. 83, 153–159.

53. Haelterman, N.A., Yoon, W.H., Sandoval, H., Jaiswal, M., Shulman, J.M., and Bellen, H.J. (2014). A mitocentric view of Parkinson’s disease. Annu. Rev. Neurosci. 37, 137–159.

54. Wang, S., Zhang, X., Guo, Y., Rong, H., and Liu, T. (2017). The long noncoding RNA HOTAIR promotes Parkinson’s disease by upregulating LRRK2 expression. Oncotarget 8, 24449–24456.

55. DeJesus-Hernandez, M., Mackenzie, I.R., Boeve, B.F., Boxer, A.L., Baker, M., Rutherford, N.J., Nicholson, A.M., Finch, N.A., Flynn, H., Adamson, J., et al. (2011). Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Nature 72, 245–256.

56. Zu, T., Liu, Y., Báñez-Coronel, M., Reid, T., Pletnikova, O., Lewis, J., Miller, T.M., Harms, M.B., Falchook, A.E., Subramony, S.H., et al. (2013). RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc. Natl. Acad. Sci. USA 110, E4968–E4977.

57. Mizielinska, S., Lashley, T., Norona, F.E., Clayton, E.L., Ridler, C.E., Fratta, P., and Isaacs, A.M. (2013). C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol. 126, 845–857.

58. Lagier-Tourenne, C., Baughn, M., Rigo, F., Sun, S., Liu, P., Li, H.R., Jiang, J., Watt, A.T., Chun, S., Katz, M., et al. (2013). Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl. Acad. Sci. USA 110, E4530–E4539.

59. Pokrišhevsky, E., Grad, L.I., Yousefi, M., Wang, J., Mackenize, I.R., and Cashman, N.R. (2012). Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis. PLoS One 7, e35050.

60. Wang, X., Arai, S., Song, X., Reichart, D., Du, K., Pascual, G., Tempst, P., Rosenfeld, M.G., Glass, C.K., and Kurokawa, R. (2008). Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature 454, 126–130.

61. Doi, H., Okamura, K., Baur, P.O., Furuikawa, Y., Shimizu, H., Kurosaawa, M., Machida, Y., Miyazaki, H., Mitsu, K., Kurovova, Y., et al. (2008). RNA-binding protein TLS is a major nuclear aggregate-interacting protein in huntingtin exon 1 with expanded polyglutamine-expressing cells. J. Biol. Chem. 283, 6489–6500.